Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing
At the HIV Analyst & Investor Event on Tuesday, Gilead Sciences Inc. (NASDAQ:GILD) revealed that it is developing a ...
STAT2d
Gilead to test once-a-year HIV prevention shot
Gilead is going to start testing a drug it believes could prevent HIV infection with just a single shot every year.
FiercePharma2d
With Biktarvy patent cliff ahead, Gilead lays out a plan to keep the HIV crown with 7 launches through 2033
Gilead Sciences’ top money maker Biktarvy has been the company’s crown jewel for years now, but with the HIV med inching ...
Gilead Sciences: Long-Term Growth Prospects in HIV Treatment Drive Buy Rating
J.P. Morgan analyst Chris Schott has maintained their bullish stance on GILD stock, giving a Buy rating yesterday.Pick the best stocks and ...
STAT1d
Pharmalittle: We’re reading about unsupported drug price hikes, an annual HIV prevention shot, and more
Gilead plans to begin Phase 3 testing soon for a drug it believes could prevent HIV infection with a single shot every year ...
Gilead’s twice-yearly shot could help end AIDS. But will it get to everyone who needs it?
A twice-yearly shot could end AIDS, but will it reach everyone who needs it? Gilead's HIV prevention drug is 100% effective ...
FiercePharma1d
ICER calls out Gilead, J&J, Novartis and more in latest report on 'unsupported' price increases
In the Institute for Clinical and Economic Review’s (ICER’s) annual price-hike report, the U.S. | The U.S. watchdog is taking ...
Fact Check: HIV drug prevents infections, but not a new 'cure' for AIDS
A drug used to treat HIV that has also shown promise in preventing infections is not a cure for those already infected, as ...
The Conversation on MSN13d
HIV: there’s hope for a cure – where we stand now
Thumbi Ndung’u consults for Gilead Sciences, Inc. He has received HIV cure-related research grants from Gilead Sciences, Inc, ...
health.wusf.usf.edu1d
This drug is the 'breakthrough of the year.' It could end the HIV epidemic
That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...
Sell Rating for GlaxoSmithKline Amidst Competitive Pressures from Gilead in HIV Market
Graham Parry, an analyst from Bank of America Securities, maintained the Sell rating on GlaxoSmithKline (GSK – Research Report). The associated ...
WLRN1d
This drug is the 'breakthrough of the year' -- and it could mean the end of the HIV epidemic
That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...